Wall Street analysts expect that Cytokinetics, Inc. (NASDAQ:CYTK) will announce earnings of ($0.71) per share for the current fiscal quarter, according to Zacks Investment Research. Two analysts have issued estimates for Cytokinetics’ earnings, with the highest EPS estimate coming in at ($0.33) and the lowest estimate coming in at ($0.93). Cytokinetics reported earnings of $0.16 per share during the same quarter last year, which indicates a negative year over year growth rate of 543.8%. The business is scheduled to announce its next earnings results on Thursday, February 15th.
On average, analysts expect that Cytokinetics will report full-year earnings of ($2.40) per share for the current financial year, with EPS estimates ranging from ($2.76) to ($2.14). For the next financial year, analysts forecast that the company will report earnings of ($1.74) per share, with EPS estimates ranging from ($2.63) to ($1.11). Zacks’ EPS averages are an average based on a survey of analysts that cover Cytokinetics.
Cytokinetics (NASDAQ:CYTK) last posted its earnings results on Thursday, October 26th. The biopharmaceutical company reported ($0.60) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.64) by $0.04. The business had revenue of $6.18 million for the quarter, compared to analyst estimates of $5.35 million. Cytokinetics had a negative net margin of 172.27% and a negative return on equity of 62.64%.
Cytokinetics (CYTK) traded down $0.15 during trading hours on Friday, hitting $9.80. 284,912 shares of the company traded hands, compared to its average volume of 461,850. The company has a debt-to-equity ratio of 0.14, a current ratio of 7.60 and a quick ratio of 7.60. The firm has a market cap of $528.07, a price-to-earnings ratio of -5.90 and a beta of 1.61. Cytokinetics has a 1-year low of $7.00 and a 1-year high of $17.20.
In other Cytokinetics news, CEO Robert I. Blum sold 5,000 shares of the company’s stock in a transaction dated Wednesday, November 1st. The shares were sold at an average price of $13.51, for a total value of $67,550.00. Following the completion of the transaction, the chief executive officer now owns 70,180 shares in the company, valued at approximately $948,131.80. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Caryn Gordon Mcdowell sold 4,260 shares of the company’s stock in a transaction dated Thursday, November 2nd. The stock was sold at an average price of $12.94, for a total transaction of $55,124.40. Following the completion of the transaction, the insider now owns 17,982 shares of the company’s stock, valued at approximately $232,687.08. The disclosure for this sale can be found here. In the last 90 days, insiders sold 19,290 shares of company stock valued at $245,084. 7.20% of the stock is owned by insiders.
Hedge funds and other institutional investors have recently bought and sold shares of the business. Birchview Capital LP bought a new position in shares of Cytokinetics in the third quarter valued at approximately $145,000. Piedmont Investment Advisors LLC bought a new position in shares of Cytokinetics in the third quarter valued at approximately $159,000. Dynamic Technology Lab Private Ltd bought a new position in shares of Cytokinetics in the second quarter valued at approximately $177,000. Fox Run Management L.L.C. bought a new position in shares of Cytokinetics in the fourth quarter valued at approximately $181,000. Finally, GSA Capital Partners LLP bought a new position in shares of Cytokinetics in the third quarter valued at approximately $187,000. Hedge funds and other institutional investors own 75.25% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “Zacks: Brokerages Expect Cytokinetics, Inc. (CYTK) Will Announce Earnings of -$0.71 Per Share” was originally published by American Banking News and is owned by of American Banking News. If you are reading this article on another website, it was stolen and republished in violation of US & international trademark & copyright legislation. The legal version of this article can be viewed at https://www.americanbankingnews.com/2018/01/28/zacks-brokerages-expect-cytokinetics-inc-cytk-will-announce-earnings-of-0-71-per-share.html.
Cytokinetics, Incorporated is a late-stage biopharmaceutical company. The Company is focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. It is focused on the discovery and development of small molecule therapeutics that modulate muscle function for the treatment of serious diseases and medical conditions.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Cytokinetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytokinetics and related companies with MarketBeat.com's FREE daily email newsletter.